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Resumo 
 
O ferro é um dos elementos chave para as funções celulares 
básicas. Se a sua homeostasia não for corretamente mantida, poderá 
ocorrer uma sobrecarga de ferro no organismo. Os doentes com 
Hemocromatose Hereditária (HH), com a mutação C282Y no gene HFE, 
possuem uma progressiva e severa sobrecarga de ferro que, se não for 
tratada, pode levar a dano nos tecidos, podendo mesmo culminar em 
cirrose hepática e carcinoma. Tendo em conta que o dano tecidular pode 
estar associado ao stress oxidativo (OS) causado pela sobrecarga de 
ferro, é importante perceber de que modo atua o sistema de defesa 
contra o OS nas células dos doentes HH com forma severa de 
sobrecarga de ferro. Poucos estudos foram realizados sobre o potencial 
estado oxidante nas células do sangue, onde se encontra uma das 
maiores fontes de reações oxidativas. Contudo, num estudo recente foi 
demonstrado que linfócitos de doentes com HH, quando comparados 
com linfócitos de controlos e pacientes com formas secundárias de 
hemocromatose, apresentam uma maior proteção relativamente à 
instabilidade cromossómica (CI) induzida por 1,2:3,4 diepoxibutano 
(DEB) – um agente alquilante que provoca OS. Este estudo sugere uma 
resposta adaptativa das células HH a níveis elevados de OS. No 
entanto, ainda não se sabe se esta mesma resposta pode ser observada 
com outras fontes de toxicidade do ferro, nomeadamente na presença 
de bleomicina (BLM) cuja atividade depende da formação de complexos 
com o ferro não ligado à transferrina (NTBI). 
Para compreender melhor o estado oxidante das células do 
sangue dos doentes HH e a suposta resposta adaptativa das células dos 
doentes de HH à toxicidade do ferro, foi feita a análise de dois 
parâmetros de OS selecionados: avaliação da depleção da glutationa 
reduzida (GSH) e da peroxidação lipídica (LPO). Esta análise foi 
efetuada em eritrócitos (RBC) e linfócitos (LY), tanto no tempo 0 como 
passadas 36h em cultura, com ou sem indução de OS. O segundo 
objetivo deste trabalho foi testar se a BLM promove uma resposta 
adaptativa à CI comparável à que foi observada com o DEB.  
Tanto a caracterização dos parâmetros de OS como os estudos 
de CI foram efetuados em células de 5 doentes com HH, com elevada 
sobrecarga de ferro, e em células de 6 dadores saudáveis (HD). 
Os resultados mostraram que os RBC dos doentes com HH, 
comparativamente com os dos HD, apresentam uma maior depleção de 
GSH e maior LPO, quer ao dia 0 quer após 36h em meio de cultura. 
Estes resultados sugerem um aumento de OS nos RBC dos doentes. 
Contrariamente, os LY dos doentes de HH apresentaram menor 
depleção de GSH após 36h de cultura, sendo esta mais notória nas 
culturas induzidas com DEB e BLM. Adicionalmente, os níveis de LPO 
são menores em LY dos doentes de HH, após 36h de cultura, 
comparativamente com os dos HD. Isto sugere que culturas de LY, quer 
não-tratadas quer tratadas com DEB ou BLM, têm um algum tipo de 
mecanismo de defesa contra o OS, ainda não compreendido. A 
frequência de CI induzida por BLM em LY de doentes com HH não é 
significativamente diferente da observada em LY de HD, não se 
observando assim uma diferença na capacidade de resposta à BLM, 
entre células de doentes e controlos. Pode-se então concluir que a 
toxicidade induzida por BLM não aumenta a CI em células de doentes 
com HH com forma severa de sobrecarga de ferro. 
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Abstract 
 
Iron is a key element for basic cellular functions. If iron 
homeostasis is not maintained it may lead to iron overload. Patients with 
Hereditary Hemochromatosis (HH) and with the C282Y HFE mutation 
have a progressive severe iron overload that, if it is not treated, may lead 
to tissue damage, that mostly culminate in hepatic cirrhosis and 
carcinoma. Having in mind that  tissue damage in HH may be related with 
oxidative stress (OS) caused by iron toxicity, it is important to understand 
in what way the OS defense is acting in cells from HH patients with 
severe forms of iron overload. Few studies have been performed 
concerning the eventual prooxidant state in blood cells, which bear a 
major source of OS. Nevertheless, in a recent study it was shown that 
cultured lymphocytes (LY) from HH, when compared with cultured LY 
from controls and patients with secondary forms of hemochromatosis, 
have an increased protection against chromosome instability (CI) induced 
by 1,2:3,4 diepoxybutane (DEB) – an OS-related alkylating agent. This 
suggests an adaptive response of HH cells to the high level of OS. 
However, it is not known yet if the same response can be observed with 
other sources of iron toxicity, namely in the presence of bleomycin (BLM), 
that acts forming a complex with non-transferrin bound iron (NTBI). 
In order to better understand the oxidant status of HH blood cells 
and the putative adaptive response of HH cells to iron toxicity, a study 
was performed to characterize two selected OS parameters: evaluation of 
reduced glutathione (GSH) depletion and of lipid peroxidation (LPO). The 
study was performed in red blood cells (RBC) and lymphocytes (LY), 
either basal and after 36h in culture, with and without induction of OS. 
Induction of OS was performed with DEB and with BLM. A second 
objective of the present work was to test if the previously observed 
adaptive response of HH cells to DEB-induced OS can also be observed 
after induction with BLM.  
Characterization of the OS parameters was performed in RBC 
and LY from 5 HH patients with severe iron overload and 6 healthy 
donors (HD), at day 0 and after 36h of culture, non-treated and treated 
with DEB or BLM. Studies of CI were performed in BLM-induced LY from 
the same 5 HH patients and 6 HD. 
The results show that RBC from HH patients, compared with 
those from HD, have a larger GSH depletion and more LPO, either at day 
0 and after 36h in culture medium. This suggests an increased level of 
OS in HH RBC. On the contrary, LY from HH patients present less GSH 
depletion after 36h of culture than LY from HD, being this effect more 
pronounced in DEB and BLM-treated cultures. Additionally, LPO levels 
were decreased in LY from HH patients after 36h of culture when 
compared with LY from HD. This result suggests that HH cultured LY, 
either non-treated or treated with DEB and BLM, have a still not 
completely understood mechanism of defense against OS. BLM-induced 
CI in cultured LY from HH patients was not different from the observed in 
cultured LY from HD. Therefore, we can postulate that toxicity induced by 
BLM did not increased CI in cells from HH patients with severe iron 
overload. 
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Abbreviations 
•OH – hydroxyl radical,  
BLM – bleomycin  
BMP – bone morphogenetic protein  
C/EBPα – CCAAT/enhancer-binding protein α 
CAT – catalase 
CHOP – C/EBP homologous protein 
CI – chromosome instability  
CREBH – cyclic AMP response element-binding protein H 
DCYTB – duodenal cytochrome b 
DEB – 1,2:3,4 diepoxybutane  
DMT – divalent metal transporter  
DNA – deoxyribonucleic acid 
DTNB – 5,5-dithio-bis (2-nitrobenzoic acid)  
EDTA – ethylenediamine tetra-acetic acid 
Fe – iron 
GPx – glutathione peroxidase 
GR – glutathione reductase 
GSH – reduced glutathione   
GST – glutathione transferase  
H2O2 – hydrogen peroxide 
HCL – hydrochloric acid 
HD – healthy donors 
HFE – hemochromatosis gene 
HFE – hemochromatosis protein 
HH – hereditary hemochromatosis 
ICL – inter-strand cross-links  
IL – interleukin  
IRE– iron-responsive elements 
IRP – iron regulatory proteins 
KCL – potassium chloride 
LIP – labile iron pool 
LPO – lipid peroxidation 
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LY – lymphocytes 
MAP – mitogen-activated protein kinase 
MHC – major histocomptability complex 
NADPH – nicotinamide adenine dinucleotide phosphate 
NO• – nitric oxide, 
NTBI – non-transferrin bound iron  
O2•
-
 - superoxide 
ONOO
–
 – peroxynitrite 
OS – oxidative stress 
PBS – phosphate buffer sodium 
PL - plasma 
RBC – red blood cells 
ROS – reactive oxygen species  
RT – room temperature  
SEM – standard error mean 
SH – thiol group 
SLC – soluble carrier 
SMAD – Sma and Mad related family 
SOD – superoxide dismutase  
STAT – transducer and activator of transcription 
TBARS – thiobarbituric acid-reactive substance 
Tf – transferrin 
TfR – transferrin receptor  
TLR – toll-like receptor 
TS – transferrin saturation  
wb – whole blood  
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1 Iron 
Iron is a key element for basic cellular functions. It is used as a cofactor for 
fundamental biochemical activities, such as oxygen transport, energy metabolism and 
DNA synthesis. Due to flexible coordination chemistry and redox activity, iron allows 
protein binding, electrons transferring or catalytic reactions mediation (Galaris & 
Pantopoulos, 2008). However, these chemical reactions induce the production of 
reactive oxygen species (ROS), and the generation of highly reactive radicals (such as 
the hydroxyl radical (•OH)) through Fenton chemistry (Koppenol, 1993), which may 
lead to oxidative stress (OS) and cellular damage (Galaris & Pantopoulos, 2008). Iron 
levels within cells must be precisely regulated to promote essential functions and 
provide an appropriate abundance to maintain adequate stores and concomitantly 
minimize the risk of potential toxicity (Hershko, 2007; Mackenzie et al., 2008). The 
majority of body iron (at least 2.1 g) is inside the hemoglobin of red blood cells (RBC) 
used during erythroipoiesis and oxygen transport. Significant amounts are also present 
in macrophages (up to 600 mg) and in the myoglobin of muscles (∼ 300 mg), whereas 
excess body iron (∼ 1 g) is stored in the liver (Olsson & Norrby, 2008) (Figure 1).  
 
 
Figure 1 – Distribution of iron in adults (original figure) 
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There are no mechanisms for iron excretion; iron is only lost during bleeding or 
sloughing of mucosal and skin cells. Thus, balance must be maintained by a rigid 
control of dietary iron absorption.  
1.1 Metabolism of iron 
A typical human adult absorbs 1–2 mg of iron per day from the diet (Moyer et 
al., 2011). Iron is taken up from the lumen of the intestine by the duodenal villus cells 
involving reduction of Fe
3+
 by ferric reductases, such as DCYTB (duodenal cytochrome 
b). The subsequent transport of Fe
2+
 across the apical membrane of enterocytes is done 
by DMT1 (divalent metal transporter 1), a membrane-bound protein transporter 
(SLC11A2 group). Fe
2+
 is processed by the enterocytes and exported, through 
ferroportin (SLC11A3 group), across the basolateral membrane into the bloodstream. 
The ferroportin-mediated efflux of Fe
2+
 is coupled by its re-oxidation to Fe
3+
, catalysed 
by the membrane-bound hephaestin or a copper ferroxidase homologous ceruloplasmin 
present in plasma (Yeh et al., 2009). The Fe
3+ 
binds to apo-transferrin to form 
transferrin (Tf) which circulates in the blood serum and serves to transport iron to other 
organs, maintaining Fe
+3 
in a redox-inert state (Nelson et al., 2010) (Figure 2). 
 
Figure 2 – Iron import, utilization and export pathways by enterocytes (Kucukakin et al., 2011) 
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The ferroportin-mediated efflux of Fe
2+
 is negatively regulated by hepcidin, a 
liver-derived peptide hormone that binds to ferroportin and promotes its 
phosphorylation, internalization and lysosomal degradation (Nemeth & Ganz, 2009). 
Hepcidin accumulates following iron intake and under inflammatory conditions, 
resulting in decreased dietary-iron absorption and iron retention in macrophages. 
Iron activates the expression of BMP6 (bone morphogenetic protein 6) in the 
liver (Kautz et al., 2008) and intestine (Arndt et al., 2010) which leads to 
phosphorylation of SMAD1/5/8 (Sma and Mad related family) and translocation of 
SMAD4 to the nucleus (Figure 3), where it promotes hepcidin transcription upon 
binding to proximal and distal sites on its promoter (Kautz et al., 2008).  
 
 
Figure 3 – The hepcidin iron-sensing machinery (Pietrangelo, 2010) 
Furthermore, basal hepcidin transcription requires C/EBPα (CCAAT/enhancer-
binding protein α) (Courselaud et al., 2002). Ramey and co-workers (Ramey et al., 
2009) proposed that hepcidin responds to increased Tf saturation by a mechanism 
requiring a cross-talk between BMP and MAP (mitogen-activated protein kinase) 
signalling. Supplementary cofactors are needed, including the hemochromatosis protein 
(HFE), TfR2 and the BMP co-receptor hemojuvelin (Lee & Beutler, 2009). The 
PART I – Introduction 
8 
 
 
cytokine IL-6 (interleukin-6) induces hepcidin transcription via STAT3 (signal 
transducer and activator of transcription 3) phosphorylation and translocation to the 
nucleus for binding to a proximal promoter element (Fleming, 2008) while IL-1β 
activates hepcidin via the C/EBPα and BMP/SMAD pathways (Matak et al., 2009). 
Stress in endoplasmic reticulum activates hepcidin transcription via CREBH (cyclic 
AMP response element-binding protein H) (Vecchi et al., 2009) and/or CHOP (C/EBP 
homologous protein) (Oliveira et al., 2009). In macrophages lipopolysaccharide can 
also promote autocrine activation of hepcidin through TLR4 (Toll-like receptor 4) 
signalling (Peyssonnaux et al., 2006). Downregulation of hepcidin involves EPO 
(erythropoietin) signalling, which promotes the decreased binding C/EBPα to its 
promoter (Pinto et al., 2008). The cellular storage of iron mainly involves ferritin. One 
molecule of ferritin provides storage space for up to 4500 Fe
3+
 ions in the form of ferric 
oxy-hydroxide phosphate. Iron stored within ferritin is considered to be bioavailable 
and may be mobilized for metabolic purposes(Wang & Pantopoulos, 2011). 
The process of cellular iron uptake and storage is regulated by iron regulatory 
proteins (IRP), cytosolic trans regulators able to bind to specific RNA stem-loop 
structures called iron-responsive elements. The first binding mechanism is an iron–
sulphur cluster [4Fe–4S] converting IRP1 to the cytosolic isoform of aconitase. A 
second mechanism depends on chelatable labile iron pool (LIP) mediated degradation of 
the IRP1 apoprotein (reviewed in (Wang & Pantopoulos, 2011)). The iron regulates the 
level of the ubiquitin ligase that is responsible for IRP2 degradation (Nicolas et al., 
2003). 
LIP is defined as a low-molecular weight pool of weakly chelated iron that 
rapidly passes through the cell. LIP represents only a minor fraction of the total cellular 
iron (3–5%). For instance, citrate, phosphate and other organic ions, carbohydrates and 
carboxylates, nucleotides and nucleosides, polypeptides and phospholipids are some of 
the ligands with low affinity to iron ions (Marcin, 2003). 
 
If one or more components of the blood iron-sensing machinery fail, iron 
homeostasis is not maintained, which may lead to an iron overload in some tissues. 
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1.2 Iron overload and OS 
ROS and reactive nitrogen species, such as •OH, H2O2, superoxide (O2•
–
), nitric 
oxide (NO•), peroxynitrite (ONOO–), and others, are major sources of OS in cells 
(Orrenius et al., 2007). When reactive species are present as a result of OS, redox active 
metal ions localized or bound to the DNA react to form highly reactive •OH in 
immediate proximity to deoxyribonucleic acid (DNA). •OH then abstracts the 4’ 
hydrogen atom from the deoxyribose sugar backbone, leaving a DNA radical adduct 
that rearranges, ultimately cleaving the phosphodiester backbone and resulting in strand 
scission (Perron & Brumaghim, 2009). DNA damage of both types (strand breakage or 
base damage) can ultimately result in genetic mutations, cancer, or cell death (Jomova 
& Valko, 2011).  
 
Iron-mediated DNA damage is primarily thought to originate from solvated iron 
that is not bound to proteins (such as hemoglobin, Tf, or ferritin (Andrews, 2004)). In an 
iron-overload situation the levels of plasma iron exceed the saturation capacity of Tf, 
promoting the accumulation of the non-transferrin-bound iron (NTBI). NTBI was 
shown to promote the formation of free •OH and to accelerate the peroxidation of 
membrane lipids in vitro, consequently leading to OS followed by DNA damage.  
Cells contain a large number of protective agents and defense mechanisms to 
prevent or repair the damage caused by ROS, and also to regulate redox-sensitive 
signaling pathways. Antioxidants are typically categorized in the following categories: 
Small molecule antioxidants – including both water-soluble compounds, such as 
Vitamin C or glutathione, and lipid soluble compounds, such as Vitamin E, carotenes, 
lipoic acid, and Coenzyme Q10; Large molecule “enzyme” antioxidants – such as 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) (Sies, 
1991); Preventive antioxidants – including albumin, metallothionine, Tf, ceruloplasmin, 
myoglobin, and ferritin which delay the formation of new ROS, protecting the essential 
proteins (Anikó et al., 2007).  
SOD is an important endogenous antioxidant enzyme acting as the first line 
defense system against ROS, catalyzing the dismutation of O2•
-
 in to H2O2. CAT is 
usually located in the peroxisome and decomposes H2O2 into H2O and molecular 
oxygen. GPx is present in the cytoplasm of the cells, and catalyses the reduction of 
H2O2 to H2O, with the simultaneous oxidation of reduced glutathione (GSH). GSH is a 
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tripeptide and a powerful antioxidant present within the cytosol of cells and is the major 
intracellular non-protein thiol (SH) compound. SH groups of GSH react with H2O2 and 
•OH, preventing tissue damage. Glutathione reductase (GR) is a flavoprotein enzyme 
that regenerates GSH from oxidized glutathione in the presence of NADPH 
(Nicotinamide adenine dinucleotide phosphate). Vitamins C and E are non-enzymatic 
endogenous antioxidant present within normal cells that react with free radicals to form 
less reactive radicals (Siems et al., 2000; Pandey & Rizvi, 2011). Glutathione 
transferase (GST) is one of the most important antioxidants present in blood cells, 
which catalyzes the conjugation of GSH with electrophiles (carbon, oxygen, nitrogen). 
Isoenzymes expression of GST in tissues is very different and sometimes their depletion 
is associated with various pathologies.  
 
In an iron-overload situation defense mechanisms against OS are essential to 
prevent the consequences of DNA damage in tissues. Therefore, in disorders presenting 
very severe forms of iron overload, where tissue damage already occurs, it is important 
to understand in what way the OS defense is acting.  
2 Hemochromatosis  
2.1 Disorders of iron overload 
Iron storage/overload disorder was first described in 1865 by the French 
physician Armand Trousseau, from an autopsy of a patient with diabetes presented with 
“bronze-like appearance”. The liver was “granular, of a uniform greyish-yellow colour, 
and very dense”(Trousseau, 1865). In 1889 the German pathologist Friedrich Daniel 
Von Recklinghausen proposed the term “hemochromatosis” (Von Recklinghausen, 
1889), which was associated to iron metabolism for the first time in 1935 by Joseph H. 
Sheldon (Sheldon, 1935). 
Currently, hemochromatosis is defined as iron overload with a primary or 
secondary cause. Primary iron overload is associated to hereditary iron overload 
disorder. The term secondary iron overload is used to describe additional mechanisms 
which origin an iron overload with no genetic basis: metabolic problems that improve 
the continuous iron uptake by enterocytes may lead to a high storage into body; a 
combination of excess iron absorption and red cell transfusions, as well as iatrogenic 
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iron therapy, can facilitate a secondary iron overload; the end-stage liver disease (Cotler 
et al., 1998) caused by excess alcohol consumption (Fletcher et al., 2003) and/or 
chronic hepatitis C (Ludwig et al., 1997) may also cause secondary iron overload . A 
differential diagnosis of iron overload in Human is shown in Table 1. 
Table 1 – Human diseases associated with iron overload (adapted from (Janssen & Swinkels, 2009)) 
Hereditary iron overload Acquired iron overload Other 
 HFE-associated HH (type 1) 
 C282Y homozygosity 
 Or C282Y/H63D compound heterozygosity 
 Non-HFE-associated HH 
 Type 2A hemojuvelin mutations 
 Type 2B hepcidin mutations 
 Type 3 TfR2 mutations 
 Type 4 ferroportin mutations 
 Other 
 H-ferritin IRE 
 Hemoxygenase deficiency 
 Neonatal iron overload 
 Aceruloplasminemia 
 Congenital atransferrinemia or 
hypotransferrinemia 
 DMT1 mutations 
 Iron loading anemias 
 Ineffective erythropoiesis 
 Thalassemic syndromes 
 Sideroblastic anemia 
 Myelodysplastic syndrome 
 Congenital dyserythropoiesis 
 Increased erythropoiesis 
 Chronic hemolytic anemia 
 Parenteral iron overload 
(including multiple blood 
transfusions) 
 Metabolic syndrome 
 Obesitas 
 Hypertension 
 Insulin resistance 
 Chronic liver disease 
 Hepatitis 
 Alcohol abuse  
 Non-alcoholic 
steatohepatitis 
 Porphyria cutanea tarda 
 Iron overload in sub-
Saharan Africa 
2.2 Hereditary hemochromatosis 
Hemochromatosis, as familiar disorder, was first described by Boulin & Bamberger 
in 1953 (Boulin, 1953); twenty years later Simon et al (Simon et al., 1975; Simon et al., 
1976; Simon et al., 1977) confirmed that hemochromatosis is linked to the major 
histocompatibility complex (MHC) on chromosome 6. The identification of the 
Hereditary Hemochromatosis (HH) gene came only in 1996, and was located in the 
short arm of chromosome 6 (Feder et al., 1996), firstly called HLA-H and then renamed 
HFE (to avoid confusion with an HLA pseudo-gene already called HLA-H) (Bodmer et 
al., 1997). Nowadays it is known that hemochromatosis gene (HFE) encodes an HLA-A 
class 1-like protein and is located on 6p21.3, (Figure 4) with 4 megabases (Mb) 
telomeric in the human leukocyte antigen region (HLA).  
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Figure 4 – Chromosome 6, an approximate location of HFE (original figure) 
The HFE mutation C282Y is the most commonly found in hemochromatosis, 
being present in homozygosity in 90 to 95% of all cases, with a prevalence among white 
subjects of 1:200 to 1:300 (Merryweather-Clarke et al., 1997). It is a single mutation of 
G to A at nucleotide 845, resulting in the substitution of tyrosine for cysteine at amino 
acid 282, known as the Cys282Tyr (Feder et al., 1996). This mutation disrupts a 
disulfide bond that is required for HFE to bind β2-microglobulin and is transported to 
the cell surface and endosomal membranes, where it interacts with TfR1, forming a 
complex which is affected by intracellular levels of iron (Schmidt et al., 2008). In the 
presence of increased saturation of serum Tf, HFE dissociates from TfR1 and is free to 
bind TfR2. HFE interacts also with TfR2 forming an iron-sensing complex that 
modulates hepcidin expression in response to blood levels of diferric Tf (Goswami & 
Andrews, 2006). 
Currently, HFE related HH is defined by the presence of C282Y in 
homozygosity, together with the presence of liver iron overload. In spite of the 
progressive and severe iron overload, the clinical presentation may be variable, ranging 
from simple biochemical abnormalities to severe organ damage. Several studies aimed 
to understand the cause of this variability. In a recent paper it was shown that the setting 
of CD8
+
 T-lymphocytes numbers can be a relevant modifier of the phenotypic 
expression in HH. In fact, in a previous study it was already shown that a large 
proportion of HH patients have consistently low CD8
+
 T-lymphocyte numbers 
correlating with a more severe expression of iron overload (Reimao et al., 1991; Porto 
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et al., 1994; Porto et al., 1997; de Sousa & Porto, 1998). Low total lymphocyte counts, 
reflective of low CD8
+
 T-cell counts, were also shown in HH patients from the north of 
Portugal (Porto et al., 2001) and from Alabama (United States) (Barton et al., 2005). 
The first diagnostic phase of HH is the measurement of serum iron, Tf and 
ferritin; serum ferritin levels > 200 µg/L in women or > 300 µg/L in men, and 
transferrin saturation (TS) > 45% in women or > 55% in men, are the criteria for case-
finding (Pietrangelo, 2010). TS is the most sensitive parameter for identification of 
susceptibility for HH (Janssen & Swinkels, 2009). If the TS is increased a genetic 
evaluation should be done. When HFE test is positive, iron overload can be followed by 
magnetic resonance imaging evaluation – a non-invasive technique useful for 
identification and management of these disorders. However a negative HFE test does 
not exclude the possibility of a subject developing phenotypic disease. Therefore 
hyperferritinemia unrelated to iron overload must be excluded as well as secondary iron 
overload or other disorders such as hepatocyte injury, alcoholic or viral hepatitis, or 
systemic inflammatory disorders. In these cases, it would be important a liver biopsy 
histological evaluation. 
2.2.1 OS and cancer in HH patients 
The most common complications of non-treated HH are hepatic cirrhosis, 
cardiomyopathy, diabetes mellitus and arthropathy. They may have increased 
predisposition to malignancy, particularly liver cancer. Up to 30 percent of patients who 
develop cirrhosis will develop liver cancer, which is the leading cause of death. In 
addition, some studies have linked HH to nonhepatic malignancies, including 
esophageal cancer, colorectal cancer, malignant melanoma and lung cancer, although 
with conflicting evidence. Nevertheless, HH is not associated with an increased 
predisposition to hematologic malignancies.  
It is well established that tissue damage and cancer development in HH is related 
with OS caused by excessive iron overload. Free iron is a potent promoter of •OH 
formation that can cause increased lipid peroxidation (LPO) and depletion of chain-
breaking antioxidants (e.g. GSH). In fact, iron overload in HH has recently been 
demonstrated to inflict OS, measured as high levels of the LPO product 8 -
isoprostaglandin F2α in urine (Broedbaek et al., 2009). The result can be free radical 
damage to tissues such as liver (Crawford et al., 2012), pancreas (Cooksey et al., 2004), 
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heart (Shizukuda et al., 2011), joints (Lynch & Soslau, 2011), and skin. Such oxidative 
damage in tissues may contribute to the clinical manifestations seen in HH (Franchini, 
2006). Antioxidant enzymes such as GSH are a primary defence mechanism for 
preventing damage by ROS being also important for detoxification of drugs and 
environmental toxins (Schafer & Buettner, 2001). In iron overload situations, if activity 
of GSH is reduced, it can result in an increase of OS and hence inﬂuence progression of 
the disease. Therefore, LPO and GSH evaluations may be valuable parameters for the 
study of OS in cells from HH patients. At present, few studies have been performed 
concerning the eventual prooxidant state in blood cells, namely in red blood cells 
(RBC), which bear a major source of iron and in lymphocytes (LY) where the presence 
of NTBI can be a source of OS. 
2.2.2 Chromosome instability in cells from HH patients 
Chromosome instability (CI) is defined as a persistently high rate of numerical 
and structural alterations in chromosomes. It can occur when somatic mutations are not 
repaired, either by excess of mutagens, mainly ROS, or deficiencies in DNA repair. In 
HH, iron overload enhances the formation of ROS, and consequently may increase CI, 
which can culminate in a higher predisposition to cancer development. Most human 
cancers are characterized by CI. Indeed, when CI involves genes related with 
chromosome condensation, sister chromatid cohesion, kinetochore structure and 
function, microtubule formation and dynamics as well as checkpoints that monitor the 
progress of cell cycle, the regulation of cell proliferation will be affected (Nasmyth, 
2002). 
Nordenson and co-workers observed for the first time an increase in spontaneous 
CI in lymphocytes from hemochromatosis patients (Nordenson et al., 1992). At time, 
the genetic basis of hemochromatosis was not known, so the study population was not 
HFE genotyped. Almost 20 years later, Porto and co-workers observed in lymphocytes 
from HH patients with C282Y HFE mutation also an increase of CI when compared 
with lymphocytes from HD (Porto et al., 2009).  
For the study of pathologic situations associated with increased susceptibility to 
CI, two approaches can be performed: 1. detection of spontaneous chromosome breaks; 
2. detection of chromosome breaks induced by specific genotoxic agents. At present, 
two agents are used in cytogenetic assays for the study of situations with 
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hypersensitivity to OS: the antibiotic bleomycin (BLM) and the alkylating agent 1,2:3,4 
diepoxybutane (DEB).  
BLM is a glycopeptide antibiotic with anticancer properties produced by 
Streptomyces verticillus. It was identified in 1966 (Umezawa et al., 1966), and one of 
its mechanisms of action is breaking the DNA double helix by the production of free 
radicals, a process that is oxygen and iron dependent. High concentrations of BLM 
arrest cells in the G2/M phase of cell cycle, leading to cell death. However, recent 
studies showed that lower concentrations of BLM induce over-replication (Nakayama et 
al., 2009). It is commonly used in cytogenetic assays as a radiomimetic agent that 
causes CI. It is also used for measuring non-transferrin bound iron (NTBI); in the BLM 
assay, the BLM reacts with NTBI forming BLM-iron complex which releases OH⋅ and 
promotes DNA damage. 
DEB is a genotoxic metabolite of 1,3-butadiene produced by further epoxidation 
of 1,2-epoxybutane (Vlachodimitropoulos et al., 1997). It is also a bifunctional 
alkylating agent, being capable of inducing the formation of monoalkylated DNA 
adducts, DNA cross-links, mainly inter-strand cross-links (ICL) and DNA–protein 
cross-links. DEB-induced cytotoxicity has been related to oxidative damage. Korkina 
and co-workers (Korkina et al., 2000) identified, for the first time, the redox-dependent 
toxicity of DEB. In fact, DEB-induced DNA-DNA and DNA-protein cross-links are a 
characteristic feature of ROS-mediated damage (Michaelson-Richie et al., 2010). 
Therefore, DEB is routinely used in CI studies related with prooxidant situations. 
In a recent work Porto (Porto et al., 2009) reported that cultured lymphocytes 
from HH patients have lower CI induced by DEB when compared with both controls 
and patients with secondary forms of hemochromatosis. This suggests a still not 
completely understood adaptive response of HH cells to the high level of OS. Adaptive 
response has already been observed in other situations, in response to a high dose of a 
cytotoxic agent after repeated low-dose exposure. In order to better explore the adaptive 
response hypothesis in HH cells, further studies are needed, involving OS-related agents 
other than DEB. BLM is a good candidate, own to its affinity to NTBI in lymphocytes. 
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As previously discussed, tissue damage in HH is described to be related with OS 
caused by excessive iron overload. Thus, it is important to understand how the OS 
defense mechanisms are acting in cells of HH patients with severe forms of iron 
overload. Few studies have been performed concerning the eventual prooxidant state in 
blood cells. Therefore, the first aim of the present study was to evaluate the OS though 
measurement of OS parameters in LY and RBC, which bear various sources of OS, 
from HH patients with severe iron overload. For this purpose: two selected OS 
parameters (GSH levels and LPO) were determined in RBC and LY from HH patients 
and healthy donors, at day 0 (basal level) and after 36 hours in culture (non-treated and 
treated with DEB or BLM). 
 
It has already been described that cultured LY from HH patients have an 
increased capacity to respond to the genotoxic effect of DEB, which suggests an 
adaptive response of HH cells to the high level of OS. The second objective of the 
present study was to test the effect of BLM in LY from HH patients, and compare with 
the previously observed effect of DEB. For this purpose: CI in BLM-induced LY 
cultures from HH patients and healthy donors were evaluated. Cultures of 48 and 96 
hours were performed, with BLM induction 6 hours before culture harvesting.  
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1 Subjects 
This study includes 5 HH patients (2 males and 3 females with a mean age of 59 
years, ranging from 53 to 70 years), all homozygous for the C282Y HFE mutation and 
regularly followed up at the Hemochromatosis Outpatient Clinic of Santo António 
Hospital, Porto. Patients had, at the time of the study, severe iron overload. A total of 6 
healthy donors (HD) (5 female and 1 male with a mean age of 24 years, ranging from 19 
to 29 years) were used as controls. In each experiment, control subjects were studied in 
parallel with patients. The study was submitted and approved by the ethical committee 
of Santo António Hospital, Porto. An informed consent was obtained from each 
participant.  
For each experiment, 35 mL of blood was collected by venipuncture into 
vacuum tubes with lithium heparin, from each patient or control. 
2 Cells 
2.1 Isolation of LY and RBC 
LY and RBC were isolated from peripheral blood by a gradient density 
centrifugation method, using Histopaque solution 1077 in polypropylene centrifuge 
tubes. Briefly, 3 mL of collected blood was carefully layered on top of 3 mL of 
Histopaque 1077 in each 15 mL polypropylene tube. The tube was centrifuged at 890 × 
g for 30 min at room temperature (RT). The LY layer was carefully removed for another 
tube, using a glass Pasteur pipette, and the remaining RBC layer was removed to 
another tube. The LY layer was gently mixed with 10 mL of PBS (phosphate buffer 
sodium) 1X and then centrifuged at 840 × g for 10 min at RT to remove platelets. The 
supernatant was dispensed and 10 mL of RBC lysis solution (1 M Tris-base HCL (pH 
7.2), 5 M NaCl and 1 M MgCl2
.
6H2O) was added to LY pellet, during 10 min, to lyse 
any remaining RBC. This suspension was centrifuged at 840 × g for 10 min at RT, after 
which the supernatant was dispensed. LY pellet was resuspended with 1 mL of PBS. 
2.2 Cell preparation for the study of basal OS parameters 
In an aliquot with 250 µL of isolated RBC it was added 1 mL of RBC lysis 
solution during 15 min. This suspension was centrifuged at 180 × g for 5 min at RT. 
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The RBC pellet was dispensed and the supernatant (hemolysate) was transferred to 
another aliquot. The hemolysate and isolated LY were immediately stored at -80 ºC for 
posterior measurement of basal enzymatic antioxidant activities and LPO. 
3 Cell cultures 
Samples of whole blood (wb) and samples of plasma (PL), where RBC were 
depleted by gravity sedimentation, were used in the present study. Cultures were set 
up in RPMI 1640 (Sigma) complete medium supplemented with 15 % fetal calf serum 
(GIBCO), antibiotics (10,000 units/mL of penicillin and 10,000 μg/mL of 
streptomycin) (GIBCO) and 29 mg/mL of L-glutamine (Sigma). LY were stimulated 
with 5 μg/mL of phytohemagglutinin (GIBCO) and placed in an incubator at 37°C 
with 5 % CO2 atmosphere, for 36, 48 or 96 h.  
3.1 Exposure to DEB  
DEB ((±)-1,2:3,4-diepoxybutane, [298-18-0], D-7019 Lot 34 H3683, Sigma), 
prepared in RPMI 1640, was added to appropriate cell cultures 24 h after their initiation, 
thus exposing cells to the chemical for 12 h. DEB was added at the final concentration 
of 0,1 μg/mL. Since DEB is a genotoxic agent specific precautions were taken. All 
culture procedures were handled using appropriate gloves and in a vertical laminar flow 
hood. 
3.2 Exposure to BLM 
BLM (Bleomicina TEVA, 15000U/mL) was prepared in RPMI 1640 complete 
medium. In the appropriate experiments, BLM was added 24 h after the initiation of cell 
culture at the final concentration of 10 µg/mL. In another set of experiments, BLM was 
added 6 h before harvesting, at the final concentration of 15 µg/mL.  
3.3 Cell preparation for the study of OS parameters after 36 hours 
of culture  
After 36 h of spontaneous and BLM and DEB-induced cultures (either wb and 
PL), cells were harvested and centrifuged at 180 × g, 5 min, RT. The supernatant of PL-
cultures was dispensed. LY pellets were resuspended with 1 mL of PBS. The 
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supernatant of wb-culture was dispensed. RBC pellets were resuspended with RBC lysis 
solution (4,5 mL each tube), during 15 min at RT. This suspension was centrifuged at 
180 × g for 5 min at RT. The supernatant of RBC was stored in aliquots (1 mL of RBC 
hemolysate each). Both cell suspensions (LY and RBC) were immediately stored at -80 
ºC. OS evaluation was also performed in RBC that were put in culture medium during 
36 hours, either with and without induction with BLM and DEB. 
4 Characterization of OS parameters 
4.1 Sample processing for GSH and LPO quantification 
Cell suspension aliquots were de-frozen and spinned at 13 000 × g for 10 s at 
4ºC and the supernatants rejected. The pellet was then treated with HClO4 10 %. After a 
brief vortexing, the homogenates were centrifuged 13 000 × g for 10 min at 4 ºC. 
Aliquots of the resulting supernatants (the hemolyse were diluted 20x with HClO4 5 %) 
were used for the measurement of LPO and GSH. The pellet of LY was dissolved in 
NaOH 0,3 M and stored at -20º C for posterior protein quantification. 
4.2 GSH quantification 
GSH quantification was performed by the DTNB-GR recycling assay, based on 
the oxidation of GSH by 5,5-dithio-bis (2-nitrobenzoic acid) (DTNB), as described by 
Vandeputte and coworkers (Vandeputte et al., 1994) with some modifications (Carvalho 
et al., 2004). KHCO3 0,76 M (200 µL) was added to the supernatant (200 µL) and 
centrifuged 13,000 × g, 1 min at 4 ºC. Standard GSH corresponding to concentrations 
ranging between 0,5 and 15 nmol were also prepared. Freshly prepared reagent solution 
(DTNB 0,7 mM and NADPH 0,24 mM in sodium phosphate-EDTA buffer, pH 7,5) 
was added and incubated at 30 ºC during 15 min, in the dark. GR was added 
immediately before measuring the plate at 412 nm by spectrophotometry. The 
concentration of total GSH was calculated using a standard curve. GSH levels were 
measured as µmol of GSH per mg of protein present in LY. In RBC, GSH levels were 
measured as µmol of GSH per g of hemoglobin.  
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4.3 Protein quantification 
Protein quantification was performed according to the method of Lowry and co-
workers (Lowry et al., 1951), using bovine serum albumin as standard. 
4.4 LPO quantification 
LPO was evaluated by the thiobarbituric acid-reactive substance (TBARS) 
methodology (Buege & Aust, 1978). Results are expressed as nmol of malondialdehyde 
(MDA) equivalents per mg of protein using an extinction coefficient (ε) of 1.56 × 105 
M
-1
cm
-1
. 
5 Evaluation of CI in LY from BLM induced cultures 
After 48 and 96 h days of culture, cells were harvested after a 1 h incubation 
with 100 μL colcemid® (GIBCO) followed by hypotonic treatment with 75 mM KCl 
and fixation in 1:3 solution of acetic acid:methanol. Chromosome preparations were 
made by the standard air drying method. 
Cytogenetic analysis was performed on coded slides and an average of 91 
Giemsa-stained metaphases (mode = 100, range = 22-100) was observed. To avoid bias 
in cell selection, consecutive metaphases, which appeared intact with sufficient well-
defined chromosome morphology, were selected for the study. Each cell was scored for 
chromosome number and structural abnormalities. Achromatic areas less than a 
chromatid in width were scored as gaps; achromatic areas more than a chromatid in 
width were scored as breaks. Tri-radial and quadri-radial configurations and dicentric 
and ring chromosomes were scored as rearrangements (Figure 5). Gaps were excluded 
in the selection of chromosome aberrations and rearrangements were scored as two 
breaks. As CI parameters, percentage of aberrant cell and nº of breaks per cell were 
used. 
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Figure 5 – Examples of chromosomal aberrations in induced chromosomal breakage:[A] 
Chromatid gap; [B] chromatid break; [C] tri-radial configuration; [D] quadri-radial 
configuration; [E] others figures configurations; [F] ring chromosome. 
6 Statistical analysis 
Graph results were expressed as mean ± SEM. Statistical comparison among 
groups was estimated using two-way ANOVA, followed by the Bonferroni post hoc 
test, and comparison between two groups was estimated using unpaired t-test, both with 
GraphPad Prism, version 5.0 software. P values lower than 0,05 were considered as 
statistically significant. 
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1 Evaluation of the OS parameters 
Evaluation of OS in LY and RBC from HH patients was performed, in 
comparison with LY and RBC from HD, using two selected OS parameters: GSH and 
LPO levels. These parameters were measured at day 0 (basal) and after 36 h of culture, 
with and without induction with DEB and BLM. For OS evaluation of RBC after 36 h, 
these cells were put in culture medium and in wb-culture. For OS evaluation in LY, PL-
culture was performed. The results are shown in figures 6-9. 
1.1 GSH levels 
In both groups (HH patients and HD),a highly significant (P<0,0001) depletion 
of GSH was observed in RBC after 36 h either in culture medium and in wb-culture, 
when compared with GSH levels at day 0 (Figure 6A). 
 
 
Figure 6 – Changes in GSH levels of RBC [A] – at day 0 and after 36 h in culture medium and in 
wb-culture; 
***
P<0,001 HH patients RBC at day 0 vs RBC in culture medium and in wb-culture; 
P<0,001 HD RBC at day 0 vs RBC in culture medium and in wb-culture [B] – after 36 h in culture 
medium with and without induction with DEB and BLM; [C] – after 36 h in wb-culture with and 
without induction with DEB and BLM. Results are expressed as the mean ± SEM in the seven 
experiments. 
           HD                         HH patients 
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Addition of DEB or BLM had no effect on the level of GSH in RBC from both 
groups, HH patients and HD. Interestingly, GSH levels were consistently lower in RBC 
from HH patients when compared with RBC from HD, in all conditions tested: at day 0 
(Figure 6A), after 36 h in culture medium, with and without induction with DEB and 
BLM (Figure 6B), and after 36 h in wb-culture with and without induction with DEB 
and BLM (Figure 6C). These results are not statistically significant, probably due to the 
low number of samples tested.  
In LY from both HH patients and HD a highly significant (P<0,0001) depletion 
of GSH was observed at 36 h when compared with GSH levels at day 0, as shown in 
Figure 7A. Addition of DEB or BLM had no effect on the level of GSH in cultured LY 
from HD (Figure 7B), but an effect was observed in LY from HH patients, although the 
results are not statistically significant. Interestingly, GSH levels were consistently 
higher in LY from HH patients when compared with LY from HD, in all conditions 
tested: at day 0 (Figure 7A) and after 36 h in PL-culture with and without induction 
with DEB and BLM. These results are not statistically significant, probably due to the 
low number of samples tested. 
 
 
Figure 7 – Changes in GSH levels of LY [A] – at day 0 and after 36 h of PL-culture;  ***P<0,001 [B] 
– after 36 h of PL-culture  with and without induction with DEB and BLM. Results are expressed as 
the mean ± SEM in the four experiments. 
           HD                         HH patients 
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1.2 LPO content 
As shown in Figure 8A, HH patients exhibited a significant decrease of LPO in 
RBC after 36 h in culture when compared with the basal level (P<0,05) . This 
significant decrease was not observed in RBC from HD.  
After 36 h in culture medium (Figure 8B), LPO levels in non-treated RBC from 
HH patients were significantly higher than those from HD (P=0,0225). The addition of 
DEB or BLM had no effect on the level of LPO, both in RBC from HH patients and 
HD. 
 
 
 
Figure 8 – Changes in LPO of RBC. [A] – at day 0 and after 36 h of culture (in culture medium and 
wb-culture);
 *
P<0,05 HH patients RBC at day 0 vs RBC in culture medium and in wb-culture [B] – 
after 36h in culture medium with and without induction with DEB and BLM; 

 P=0,0225 HH 
patients RBC vs HD RBC in control culture [C] – after 36 h in wb-culture with and without 
induction with DEB and BLM;  P=0,0130 HH patients RBC vs HD RBC in wb-culture induced 
with BLM. Results are expressed as the mean ± SEMin the seven experiments.  
After 36 h in wb-culture (Figure 8C), the addition of DEB or BLM had also no 
significant effect on the levels of LPO, in RBC from both HH patients and HD, except 
for a significantly higher value observed in BLM-treated RBC from HH patients in 
comparison to the levels found in HD (P=0,0130). 
           HD                         HH patients 
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In LY from both HH patients and HD a decrease in LPO level was observed at 
36 h when compared with LPO levels at day 0, as shown in Figure 9A. However, this 
decrease was only significant in LY from HH patients. After 36 h in PL-culture (Figure 
9), the addition of DEB or BLM had no significant effect on the levels of LPO, in LY 
from both HH patients and HD. 
 
 
 
Figure 9 – Changes in LPO levels of LY [A] – at day 0 and after 36 h of PL-culture; *P<0,05 HH 
patients LY at day 0 vs after 36 h [B] – after 36 h of PL-culture with and without induction with DEB 
and BLM. Results are expressed as the mean ± SEM in the four experiments. 
  
           HD                         HH patients 
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2 Evaluation of CI in LY from BLM induced cultures 
Induced CI in LY cultured in the presence of BLM was measured by two 
parameters: percentage of aberrant cells and number of breaks per cell. The results are 
shown in Table 2. 
 
Table 2 – BLM- induced CI in LY from HH patients and HD. 48 h and 96 h cultures were 
performed with BLM induction during the last 6 h of culture. 
48h 96h 
Code 
No. 
n 
% Aberrant 
Cells 
Nº Breaks  
per cell 
n 
% Aberrant 
Cells 
Nº Breaks  
per cell 
HD 
110 - - - 100 11 0,26 
117 100 15 0,29 100 5 0,06 
124 45 4,44 0,07 100 13 0,16 
133 100 6 0,10 100 17 0,33 
135 100 12 0,25 100 7 0,07 
136 100 10 0,25 100 6 0,14 
Mean 
  
9,49 0,19 
 
9,83 0,17 
Standard derviation 
  
4,32 0,10 
 
4,67 0,11 
Coefficient of variation 
  
45,52 51,87 
 
47,45 62,70 
Variance 
  
18,65 0,01 
 
21,77 0,01 
HH patients 
1 100 12 0,19 100 3 0,03 
2 22 13,64 0,14 50 10 0,12 
3 - - - 100 10 0,16 
4 100 16 0,26 100 15 0,18 
5 100 9 0,10 100 4 0,06 
Mean 
  
12,66 0,17 
 
8,40 0,11 
Standard derviation 
  
2,94 0,07 
 
4,93 0,06 
Coefficient of variation 
  
23,23 39,99 
 
58,68 58,21 
Variance 
  
8,65 0,00 
 
24,30 0,00 
 
The first set of experiments was performed with cells from 4 HH patients and 5 
HD at 48 h of cultured LY. No significant differences were observed in number of 
chromosome breaks per cell or in percentage of aberrant cells between HD and HH 
patients (P>0,05 and P>0,05, respectively). The second set of experiments was 
performed with cells from 5 HH patients and 6 HD at 96 h of cultured LY. Similarly to 
the previous cultures, no significant differences were observed in number of 
chromosome breaks per cell or in percentage of aberrant cells between HD and HH 
patients (P>0,05 and P>0,05, respectively). 
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HH is a recessive disorder, characterized by systemic iron overload with 
consequent tissue damage. The vast majority of HH patients are homozygous for the 
C282Y mutation in HFE, a non-classical MHC class-I gene located in chromosome 6. 
The mutated protein HFE is unable to bind to the β2-microglobulin present in the 
plasma membrane of almost cells. This loss of function allows the entry of iron into 
cell, leading to iron overload. 
It is known that iron overload enhances the formation of ROS, with increasing 
risk of DNA damage as well as increased LPO and protein modifications. The oxidative 
damage in tissues contributes to the clinical manifestations seen in HH such as ﬁbrosis 
and later, cirrhosis (Franchini, 2006). Antioxidant enzymes, such as GSH, are a primary 
defence mechanism for preventing damage by ROS. In iron overload situations, the 
reduction of GSH activity can result in an increase of OS and hence inﬂuence 
progression of the disease. The relation between GSH depletion and iron homeostasis is 
not clearly understood so far. 
In the present work, selected OS parameters were evaluated in RBC and LY 
from HH patients and a comparative study was performed with RBC and LY from 
healthy donors (HD). The two selected OS parameters were GSH and LPO.  
1 Evaluation of GSH levels 
The increased depletion of GSH in RBC, from both HH and HD, at 36 h, seems 
to be associated to culture stress. The presence of DEB or BLM did not appear to be 
associated with increased depletion of GSH. This GSH depletion can occur as a 
consequence of its function as a substrate in detoxiﬁcation reactions catalyzed by GPx 
or GST (Mytilineou et al., 2002). The results of GSH levels showed that RBC from HH 
patients had more GSH depletion in comparison with RBC from HD. The measurement 
of GSH in LY showed that there is a significant depletion in the samples from HH 
comparing these levels at day 0 and after 36 h of LY culture. LY from HH patients seem 
to respond to the addition of the genotoxic agents DEB and BLM in different ways. 
Although no significant differences were observed between treatments at 36 h of cell 
culture, there is an indication of a decreased depletion in GSH when DEB or BLM is 
added. This may suggest that these patients an adaptive response, but further studies are 
needed with a larger population. 
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2 Evaluation of LPO levels 
The iron overload present in HH has been also associated to LPO in RBC 
membrane, composed by polyunsaturated fatty acid, which is extremely sensitive to 
oxidation (Ferreira et al., 1999). Besides, RBC has more LPO susceptibility, due to 
continuous exposure to OS (exposed to high oxygen tension, presence of hemoglobin-
bond iron). The results of the present work show that RBC and LY LPO levels did not 
differ significantly among groups. This contrasts with the previous study in HH patients 
that showed increased levels in HH patients (Niemelä et al., 1999). However, the study 
was perhaps limited by the relatively small sample size of the groups. 
3 Evaluation of CI in LY from BLM induced cultures 
Iron per se is capable of inducing a wide range of DNA lesions, from base 
modifications to strand breaks and adducts leading an increase of spontaneous CI (Prá et 
al., 2012). To test the effect of BLM in the defence against OS, comparatively with 
DEB (Porto et al., 2009), BLM-induced CI in LY cultures from HH patients and HD 
was analyzed. The results of the present study showed that both groups had a similar 
capacity to respond to the genotoxic agent. This effect may reflect the pathways of 
DNA repair promoted by the different DNA damage of these compounds. BLM is used 
as chemotherapeutical agent by enabling cell death via ATM/ATR. Whereas DEB, as 
bifunctional alkylating agent, promotes the majority of the cytotoxity by ICL which 
subsequently are repaired via Fanconi Anemia Proteins (Andreassen & Ren, 2009).  
BLM is a radiomimetic agent that uses Fe
2+ 
to attack DNA, which suggests that 
cells with iron overload may produce a higher level of CI. However, cells from HH 
patients did not present increased CI. It may be suggested that HH patients may have an 
increased activity of DNA repair, inactivating BLM, or an increased activity in BLM 
resistance proteins (Mir et al., 1996), BLM-hydrolase (Bokemeyer, 2008) and DNA 
polymerase β (Liu et al., 2011). These acting can be related with an adaptive response  
of HH cells, probably due to continuous high doses of endogenous iron, which activate 
CI inducers (Tedeschi et al., 1996). 
Conversely, the last result may also suggest that HH LY have normal doses of 
endogenous iron. This hypothesis may explain the low incidence of hemotological 
malignancies presented by HH patients. To better understand the true meaning of these 
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results, it would be useful to investigate the role of spontaneous and BLM-induced 
apoptosis as well as the quantification of proteins involved in BLM inactivation. 
4 Comparison of OS parameters and CI in HH 
Under GSH depletion, H2O2 endogenously produced enhances arachidonic acid 
release through cellular phospholipase A2 activation in membranes and furthermore, 
might be converted to •OH by metals such as iron. Excess accumulation of lipid 
hydroperoxides produced by LPO under intracellular GSH depletion may promote cell 
death, which may be dependent on the intensity of oxidative stress and lipid 
peroxidation. 
In this study, the apparent protection of GSH depletion in LY from HH patients, 
after 36 h of culture with BLM and the difference of LPO levels in LY among groups 
may indicate that LY from HH patients have not increased OS, in comparison with LY 
from HD. The results of CI induced by BLM in LY from HH patients corroborate these 
results.  
5 Major conclusions of the study  
The major findings and conclusions of this thesis are below highlighted: 
 
- No significant differences were observed in OS blood cells response 
between HH patients and healthy donors. Nevertheless, different 
responses to OS, measured by GSH levels, were observed between RBC 
and LY from HH patients. 
 
- BLM-induced LY from HH patients did not show increased CI, 
comparatively to HD. The decrease in CI obtained with DEB (Porto et 
al., 2009) was not observed with BLM. The different response of LY to 
the BLM-induced OS and the DEB-induced OS (Porto et al., 2009) may 
reflect different pathways of DNA repair, promoted by the different 
DNA damage of these compounds. 
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- The results of CI induced by BLM in LY from HH patients corroborate 
the results obtained through measurement of GSH and LPO, indicating that 
LY from HH patients have not increased OS, which may suggest normal 
doses of endogenous iron  
6 Future perspectives 
Considering all the results obtained in the present work, it is clear that some 
aspects would benefit from further investigation, in order to clarify several aspects of 
OS status in blood cells from HH patients as well as their drug metabolization, 
particularly bleomycin. 
Firstly, the size of groups must be increased and secondly, it will be important to 
evaluate other OS parameters (such as CAT, GPx, GST) to better clarify the true 
meaning of the results of the present work.  
Other challenge to overcome would be the elucidation of DNA repair status in 
LY from HH patients as well as the quantification of bleomycin hidrolase. This enzyme 
inactivates bleomycin B2 by hydrolysis of a carboxyamide bond of β-aminoalanine, 
protecting t cells from BLM toxicity. Recently, Okamura and co-workers suggested that 
bleomycin hydrolase gene is a suppressor gene in hepatocellular carcinoma (Okamura et 
al., 2011). HH is associated with an increased risk of hepatocellular carcinoma, so it 
will be important to understand if LY of HH patients have an increased bleomycin 
hydrolase activity, which may influence the bleomycin-induced damage in these cells. 
This study opened perspectives for future studies, namely regarding the 
hypothesis that LY from HH patients may have normal doses of endogenous iron. 
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Table 1 Serum iron, tranferrin, transferrin saturation and ferritin levels of HH patients with 
severe iron overload used in this study. 
 
Table 2 Normal range levels of serum iron, tranferrin, transferrin saturation and ferritin in 
males and females. 
Sex 
Iron 
(µg/dL) 
Tranferrin 
(mg/dL) 
Transferrin saturation 
(%) 
Ferritin 
(ng/mL) 
Male 53-167 200-370 15-45 12,80-454 
Female 50-150 200-370 15-45 2,20-178 
 
 
Code no. Sex 
Iron 
(µg/dL) 
Tranferrin 
(mg/dL) 
Transferrin saturation 
(%) 
Ferritin 
(ng/mL) 
01 Male 169 209 57 765 
02 Female 159 183 62 371 
03 Male 227 182 88 1561 
04 Female 165 185 63 1067 
05 Female 96 178 38 50 
